Genmab A/S Q3 2025 Earnings Recap

GMAB Q3 2025 November 10, 2025

Get alerts when GMAB reports next quarter

Genmab reported strong financial results for the first nine months of 2025, with total revenue increasing by 21% and operating profit up by 52%, driven by strategic investments and a robust late-stage pipeline.

Earnings Per Share Beat

$0.65 vs $0.48 est.

+35.4% surprise

Revenue Beat

1022000000 vs 1011055920 est.

+1.1% surprise

Market Reaction

1-Day +1.4%

5-Day +5.58%

30-Day +11.72%

See GMAB alongside your other holdings

Add to your portfolio — free

Key Takeaways

Proposed acquisition of Merus expected to enhance Genmab's portfolio and accelerate revenue diversification.
Strong performance of EPKINLY and Rina-S, with promising clinical data presented, including an upcoming Phase III trial for Rina-S in endometrial cancer.
Financial position remains solid with $3.4 billion in cash, allowing for continued investment in high-impact programs.
Epcoritamab is set for potential approval in second-line follicular lymphoma, with substantial data support for its expanded use in upcoming ASH presentations.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit GMAB on AllInvestView.

Next Q1 2026